---
title: "Adial Pharmaceuticals CEO Cary Claiborne set to depart after Sept. 17 annual meeting; CDO Matthew Davidson slated to succeed"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295849912.md"
description: "Adial Pharmaceuticals announced a potential leadership reshuffle following its Sept. 17, 2026 annual meeting. CEO Cary Claiborne and CFO Vinay Shah are expected to be removed if shareholder proposals pass. Matthew Davidson, currently Chief Development Officer and board member, is slated to succeed as President and CEO. The event also anticipates board turnover with resignations of legacy directors, though final decisions remain pending."
datetime: "2026-08-13T21:26:24.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295849912.md)
  - [en](https://longbridge.com/en/news/295849912.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295849912.md)
generator: "portal-rs"
---

# Adial Pharmaceuticals CEO Cary Claiborne set to depart after Sept. 17 annual meeting; CDO Matthew Davidson slated to succeed

-   Adial Pharmaceuticals flagged a potential leadership reshuffle tied to a shareholder vote at its Sept. 17, 2026 annual meeting. \* CEO Cary Claiborne is expected to be removed promptly following the meeting if the proposals pass. \* Matthew Davidson, chief development officer and a board member, is slated to become president and CEO if the vote clears. \* CFO Vinay Shah is also expected to be removed promptly following the meeting if the proposals pass. \* Board turnover is anticipated, including resignations of legacy directors, though no final decisions have been made. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Adial Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-089270), on August 13, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [ADIL.US](https://longbridge.com/en/quote/ADIL.US.md)

## Related News & Research

- [Adial Pharmaceuticals gets Nasdaq notice for falling below $2.5 million stockholders’ equity minimum](https://longbridge.com/en/news/296654275.md)
- [Adial Pharmaceuticals reports $52.0M Q2 net loss, cash $28.7M after $32M financing](https://longbridge.com/en/news/296097766.md)
- [Adial Pharmaceuticals posts bigger-than-expected Q2 net loss, hurt by acquisition charges](https://longbridge.com/en/news/296096299.md)
- [Camtek CEO Amit Rafi disposes of 6,250 shares for $1.07 million](https://longbridge.com/en/news/296101536.md)
- [Infinity Natural Resources EVP, CFO Cary D. Baetz files initial beneficial ownership statement (Form 3)](https://longbridge.com/en/news/295983095.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**